Tetrahydrofuran

Tetrahydrofuran

SCHEMBL4110507

C1CCOC1.CC(C)Br.[MgH2]

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.53
TTR P02766 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111499631-A Preparation method of olprinone hydrochloride key intermediate 山东美泰医药有限公司 2020-08-07 CN claimed
CN-118126021-A Synthesis method of ipratropium hydrochloride 杭州科巢生物科技有限公司 2024-06-04 CN disclosed
CN-116253627-A Method for synthesizing 2-bromo-6-hydroxybenzaldehyde 大连双硼医药化工有限公司 2023-06-13 CN disclosed
CN-114605240-B Preparation method of esketamine hydrochloride synthesis intermediate 宜昌人福药业有限责任公司 2023-06-06 CN disclosed
CN-115448971-A Intermediate for preparing fulvestrant and preparation method thereof 上海弼领生物技术有限公司 2022-12-09 CN disclosed
CN-111499631-B Preparation method of olprinone hydrochloride key intermediate 1-imidazo [1,2-a ] pyridin-6-yl-2-acetone 济南康桥医药科技有限公司 2021-07-30 CN disclosed
CN-109020980-B Pyrazolopyrimidine dinitrogen derivative with anti-tumor effect 华东师范大学 2020-11-20 CN disclosed
CN-111499631-A Preparation method of olprinone hydrochloride key intermediate 山东美泰医药有限公司 2020-08-07 CN disclosed
CN-110003276-A A kind of double phosphine oxidization deriving species electroluminescent organic materials of thienopyrazine and the preparation method and application thereof 中节能万润股份有限公司 2019-07-12 CN disclosed
CN-104672220-B The activator of peroxisome proliferator-activated receptor 日本化学医药株式会社 2017-09-22 CN disclosed
CN-105237533-B Tetrahydropyridine [4,3-d] miazines Hsp90 inhibitor and medical application thereof 中国药科大学 2017-03-22 CN disclosed
CN-105238415-A Liquid crystal compound containing tetrahydropyran difluoro methylene oxygen group and preparation method and application thereof SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO LTD 2016-01-13 CN disclosed
CN-105237533-A Tetrahydropyridine [4,3-d] miazines Hsp90 inhibitor and medical application thereof UNIV CHINA PHARMA 2016-01-13 CN disclosed
CN-104672220-A Activating agent for peroxisome proliferator activated receptor NIPPON CHEMIPHAR CO 2015-06-03 CN disclosed
CN-102083810-B Activator of peroxisome proliferator activated receptor NIPPON CHEMIPHAR CO.,LTD. (JP) 2014-10-29 CN disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR ALDH1A1 1587/4885TTR 2423/4885TSHR 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.